ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis

Li, Huijuan; Han, Hedong; Li, Chuling; Wu, Ranpu; Wang, Zhaofeng; Wang, Yimin; Zhan, Ping; Lv, Tangfeng; Zhang, Fang; Song, Yong*; Liu, Hongbing*南方医科大学; 南京大学; 1; y
Therapeutic Advances in Medical Oncology2023DOI: 10.1177/17588359231189430
1被引9阅读
引用收藏
分享

摘要

Objectives:Several randomized controlled trials (RCTs) indicated that first-line programmed cell death protein-1/death-ligand 1 inhibitors plus chemotherapy (PD-1/PD-L1 + chemo) led to survival benefits in extensive-stage small-cell lung cancer (ES-SCLC) compared with platinum-based chemotherapy. This study aims to identify the optimal PD-1/PD-L1 + chemo combination strategy.Methods:We included RCTs comparing PD-1/ PD-L1 + chemo versus chemo alone in ES-SCLC. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and grade > 3 treatment-related adverse events were considered. Odds ratios (ORs), hazard ratios (HRs), and their 95% confidence intervals (CIs) were extracted.Results:Six RCTs with 2600 patients were analyzed in this Bayesian network meta-analysis. Results showed that adding PD-1/PD-L1 inhibitors to chemotherapy led to significant benefits in OS (HR = 0.72, 95% CI: 0.66-0.79), PFS (HR = 0.69, 95% CI: 0.63-0.75), and ORR (OR = 1.32, 95% CI: 1.12-1.56), and no differences in toxicity were found (OR = 1.09, 95% CI: 0.92-1.30). Serplulimab plus chemotherapy was found to provide the best OS (HR = 0.63, 95% CI: 0.49-0.82), the best PFS (HR = 0.47, 95% CI: 0.38-0.59), and the best ORR (OR = 1.7, 95% CI: 1.15-2.53). Moreover, although there were no difference between PD-L1 + chemo and PD-1 + chemo regarding OS (HR = 0.99, 95% CI: 0.91-1.08) and ORR (OR = 1.27, 95% CI: 0.91-1.78), PD-1 + chemo showed a significant benefit in PFS (HR = 0.82, 95% CI: 0.68-0.98) compared with PD-L1 + chemo.Conclusions:Serplulimab plus chemotherapy seems to be superior first-line immunotherapy combination for patients with ES-SCLC. PD-1 + chemo seems to outperform PD-L1 + chemo in PFS.

学科与关键词

关键词
efficacyextensive-stage small-cell lung cancerimmunotherapy combinationsnetwork meta-analysissafety
相关
加载中…
  • Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial
    Cheng, Ying*; Han, Liang; Wu, Lin; Chen, Jun; Sun, Hongmei; Wen, Guilan; Ji, Yinghua; Dvorkin, Mikhail; Shi, Jianhua; Pan, Zhijie; Shi, Jinsheng; Wang, Xicheng; Bai, Yuansong; Melkadze, Tamar; Pan, Yueyin; Min, Xuhong; Viguro, Maksym; Li, Xingya; Zhao, Yanqiu; Yang, Junquan; Makharadze, Tamta; Arkania, Ekaterine; Kang, Wenying; Wang, Qingyu; Zhu, JunJAMA, 2022, 328(12): 1223-1232.被引 88
  • Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis
    Fu, Wenfan; Xu, Manman; Shi, Xingyuan; Jiang, Zeyong; Jian, Zhao; Lu, Dai*Therapeutic Advances in Chronic Disease, 2023, 14: 20406223231189224.
  • First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials
    Zhai, Jinzhao; Lu, Jiangyue; Zhang, Zhibo; Wang, Yuan; Li, Xiaoyan; Zhang, Sujie; Mu, Shuai; Zhi, Xiaoyu; Ge, Xiangwei; Lu, Di; Hu, Yi*; Wang, Jinliang*Cancer Medicine, 2022, 11(10): 2043-2055.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Therapeutic Advances in Medical Oncology
发表日期
2023
卷期
第 15 卷
页码
17588359231189430
DOI
10.1177/17588359231189430
语言
ENGLISH
成果收录
SCIE
资助标注
None.

作者

  • L

    Li, Huijuan (第一作者)

    1 · southern med univ · nanjing univ

  • H

    Han, Hedong

    nanjing univ

查看全部 11 位作者收起作者
  • L

    Li, Chuling

    nanjing med univ

  • W

    Wu, Ranpu

    southeast univ

  • W

    Wang, Zhaofeng

    nanjing univ

  • W

    Wang, Yimin

    nanjing med univ

  • Z

    Zhan, Ping

    nanjing univ

  • L

    Lv, Tangfeng

    nanjing univ

  • Z

    Zhang, Fang

    nanjing univ

  • S

    Song, Yong (通讯)

    1 · southern med univ · nanjing univ

  • L

    Liu, Hongbing (通讯)

    nanjing univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417